Atopic dermatitis is the first immune disease indication being studied in the clinic for soquelitinib, the Company’s selective ITK inhibitor Corvus anticipates releasing initial clinical data from trial before year-end 2024 BURLINGAME, Calif. , April 09, 2024 (GLOBE NEWSWIRE) -- Corvus

Soquelitinib advancing towards initial enrollment for registrational Phase 3 clinical trial for PTCL and randomized Phase 1 clinical trial for atopic dermatitis Orphan drug designation and new interim data from Phase 1/1b clinical trial further demonstrate soquelitinib’s potential to address the

Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT BURLINGAME, Calif. , March 13, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals , Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that the company will host a conference call and webcast on March

Poster presentation unveils Corvus’ next-generation ITK inhibitor candidates designed to deliver precise T cell modulation for immunology indications BURLINGAME, Calif. , Feb. 12, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals , Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company,

Company on track to initiate soquelitinib Phase 3 registrational clinical trial in PTCL BURLINGAME, Calif. , Feb. 08, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals , Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that the U.S.

BURLINGAME, Calif. , Feb. 06, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals , Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced the appointment of Jeffrey Arcara as Chief Business Officer. Mr. Arcara , who is a proven leader with more than 30 years of commercial

BURLINGAME, Calif. , Jan. 23, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals , Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, is deeply saddened to announce the passing of Edith P. Mitchell , M.D., a valued member of the Board of Directors.